BMS-466442 is an experimental drug that acts as a selective inhibitor of the amino acid transporter alanine serine cysteine transporter-1 (ASC-1). It indirectly increases activation of the NMDA receptor by boosting intracellular levels of the endogenous ligands glycine and D-serine. It was developed as a potential treatment for schizophrenia.
References